标题
Diagnosis and Management of Multiple Myeloma
作者
关键词
-
出版物
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Volume 327, Issue 5, Pages 464
出版商
American Medical Association (AMA)
发表日期
2022-02-02
DOI
10.1001/jama.2022.0003
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019
- (2021) Linghui Zhou et al. BMC CANCER
- Anti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
- (2020) Max S. Topp et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study
- (2020) Nizar J. Bahlis et al. LEUKEMIA
- Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN
- (2020) Peter M Voorhees et al. BLOOD
- Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma
- (2020) Nisha S. Joseph et al. JOURNAL OF CLINICAL ONCOLOGY
- Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
- (2020) Binod Dhakal et al. LEUKEMIA
- Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)
- (2020) Brian G. M. Durie et al. Blood Cancer Journal
- Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study
- (2020) Meletios Dimopoulos et al. LANCET
- Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
- (2020) Michele Cavo et al. Lancet Haematology
- Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma
- (2020) Patrick W. Mellors et al. Blood Advances
- The Global State of Hematopoietic Cell Transplantation for Multiple Myeloma: An Analysis of the Worldwide Network of Blood and Marrow Transplantation Database and the Global Burden of Disease Study
- (2020) Andrew J. Cowan et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial
- (2020) Meletios A. Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma
- (2019) Edward A. Stadtmauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study
- (2019) Suzanne Trudel et al. Blood Cancer Journal
- Natural history of multiple myeloma with de novo del(17p)
- (2019) Arjun Lakshman et al. Blood Cancer Journal
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
- (2019) Nico Gagelmann et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
- (2019) Jens Hillengass et al. LANCET ONCOLOGY
- Survival of Long-Lived Plasma Cells (LLPC): Piecing Together the Puzzle
- (2019) Shivana M. Lightman et al. Frontiers in Immunology
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR
- (2019) Maria-Victoria Mateos et al. Clinical Lymphoma Myeloma & Leukemia
- Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma
- (2019) Sagar Lonial et al. JOURNAL OF CLINICAL ONCOLOGY
- Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN
- (2019) Chad C. Bjorklund et al. LEUKEMIA
- Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone
- (2019) Timothy M. Schmidt et al. Blood Cancer Journal
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
- (2019) Michel Attal et al. LANCET
- Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
- (2019) Mark T Drayson et al. LANCET ONCOLOGY
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation
- (2018) Henry Chan et al. Clinical Lymphoma Myeloma & Leukemia
- Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group
- (2018) Richard W. Tsang et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study
- (2018) Noopur Raje et al. LANCET ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
- (2018) Brian A. Walker et al. LEUKEMIA
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance
- (2018) Robert A. Kyle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster
- (2018) Ola Landgren et al. JAMA Oncology
- Glucocorticoids in multiple myeloma: past, present, and future
- (2018) Nicholas Burwick et al. ANNALS OF HEMATOLOGY
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial
- (2018) Suzanne Trudel et al. LANCET ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis
- (2017) Philip L. McCarthy et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial
- (2017) H Goldschmidt et al. LEUKEMIA
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
- (2017) Michel Attal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group
- (2017) J Hillengass et al. Blood Cancer Journal
- Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial
- (2017) Sarah A Holstein et al. Lancet Haematology
- Unknown
- (2016) AMERICAN JOURNAL OF HEMATOLOGY
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus
- (2016) P. Musto et al. ANNALS OF ONCOLOGY
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence, incidence and survival of smoldering multiple myeloma in the United States
- (2016) A Ravindran et al. Blood Cancer Journal
- How I treat fragile myeloma patients
- (2015) A. Larocca et al. BLOOD
- Unknown
- (2015) BRITISH JOURNAL OF HAEMATOLOGY
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
- (2015) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
- (2015) Jan Krönke et al. NATURE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study
- (2014) P. G. Richardson et al. BLOOD
- Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma
- (2014) J. Martinez-Lopez et al. BLOOD
- International Myeloma Working Group Consensus Statement for the Management, Treatment, and Supportive Care of Patients With Myeloma Not Eligible for Standard Autologous Stem-Cell Transplantation
- (2014) Antonio Palumbo et al. JOURNAL OF CLINICAL ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myelome 2009-02
- (2013) X. Leleu et al. BLOOD
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients
- (2013) A K Nooka et al. LEUKEMIA
- Association of response endpoints with survival outcomes in multiple myeloma
- (2013) S Lonial et al. LEUKEMIA
- Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma
- (2013) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Myeloma as a model for the process of metastasis: implications for therapy
- (2012) I. M. Ghobrial BLOOD
- Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents
- (2012) S. Z. Usmani et al. HAEMATOLOGICA
- Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
- (2012) C Fernández de Larrea et al. LEUKEMIA
- Durable remission with salvage second autotransplants in patients with multiple myeloma
- (2011) Nina Shah et al. CANCER
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
- (2011) Gareth J Morgan et al. LANCET ONCOLOGY
- Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial
- (2011) Amrita Krishnan et al. LANCET ONCOLOGY
- The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance
- (2010) F. M. Ross et al. HAEMATOLOGICA
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma
- (2010) Jens Hillengass et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Unknown
- (2009) CLINICAL INFECTIOUS DISEASES
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
- (2009) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- Vertebroplasty in Multiple Myeloma: Outcomes in a Large Patient Series
- (2008) R.J. McDonald et al. AMERICAN JOURNAL OF NEURORADIOLOGY
- Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma
- (2008) S. Vincent Rajkumar et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now